Skip to content
10-Q

Quarterly Report

Immunocore Holdings plc IMCR

0001671927-25-000009

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 50.23M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $476.85M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $455.73M
Current Liabilities Q1 2025 · Mar 31, 2025 $149.16M
Current Liabilities Q1 2025 · Dec 31, 2024 $212.18M
Total Liabilities Q1 2025 · Mar 31, 2025 $649.53M
Total Liabilities Q1 2025 · Dec 31, 2024 $648.79M
Current Assets Q1 2025 · Mar 31, 2025 $948.63M
Current Assets Q1 2025 · Dec 31, 2024 $929.86M
Total Assets Q1 2025 · Mar 31, 2025 $1.03B
Total Assets Q1 2025 · Dec 31, 2024 $1.01B
Shares Diluted Q1 2025 · Mar 31, 2024 49.88M sh
Capex Q1 2025 · Mar 31, 2024 $430K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.59M
Stockholders Equity Q1 2025 · Mar 31, 2024 $359.53M
Stockholders Equity Q1 2025 · Dec 31, 2023 $368.84M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.49
Eps Basic Q1 2025 · Mar 31, 2024 −$0.49
Sga Expense Q1 2025 · Mar 31, 2024 $39.29M
Rd Expense Q1 2025 · Mar 31, 2024 $57.46M
Net Income Q1 2025 · Mar 31, 2024 −$24.44M
Operating Income Q1 2025 · Mar 31, 2024 −$26.49M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $246K
Revenue Q1 2025 · Mar 31, 2024 $70.5M